ProCE Banner Activity

Emerging Therapies and the Near Future Evolution in Prostate Cancer: Expert Discussion of Frequently Asked Questions

Clinical Thought

In this commentary, expert faculty address audience questions from a live symposium on emerging therapies in prostate cancer.

Released: April 01, 2023

Share

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

Exelixis, Inc.

Lilly

Pfizer, Inc.

Faculty Disclosure

Neeraj Agarwal, MD, FASCO: advisor: Avea, Exelixis, Foundation Medicine, Gilead Sciences, Lilly, Merck.

Tanya B. Dorff, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Sanofi, SeaGen.

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, Tempus; researcher: AstraZeneca, Bayer, Tempus.